Gabapentin is prescribed for a surprisingly wide range of conditions, from nerve pain and seizures to restless legs syndrome and anxiety, and each of those uses has its own set of proven alternatives. The right substitute depends almost entirely on why you’re taking gabapentin in the first place. Some people need to switch because of side effects like drowsiness or dizziness; others face concerns about misuse potential or withdrawal; and some simply aren’t getting enough relief. Whatever the reason, there are pharmacological, procedural, and non-drug options worth discussing with your prescriber.
Why People Look for Alternatives
Gabapentin was originally approved for epilepsy and a specific type of nerve pain, but off-label prescribing has expanded its reach enormously. Clinicians use it for diabetic neuropathy, migraine prevention, aggression in dementia, hot flashes, and alcohol withdrawal, among other things.1The Senior Care Pharmacist. Gabapentin: Change is in the Wind The evidence behind many of those off-label uses is thin, which is itself a reason some patients and providers reconsider the drug.
Side effects also drive the search. Gabapentin can cause sedation, weight gain, peripheral edema, and at higher doses a euphoric effect that has raised concerns about misuse and diversion. Respiratory depression is a risk when gabapentin is combined with opioids or taken by people with lung conditions.2PubMed Central. Review about gabapentin misuse, interactions, contraindications and side effects Several U.S. states have reclassified gabapentin as a controlled substance, and the United Kingdom did the same nationally.3The Senior Care Pharmacist. Gabapentin: Change is in the Wind For people already on gabapentin who want off, withdrawal can set in after as few as three weeks of use, which means the transition itself needs careful planning.
Pregabalin as the Closest Swap
Pregabalin is the most pharmacologically similar alternative to gabapentin. Both belong to the gabapentinoid class, and they share a mechanism of action. The key practical difference is that pregabalin is absorbed more predictably. Gabapentin’s absorption becomes less efficient the more you take, which means doubling the dose doesn’t necessarily double the drug’s effect. Pregabalin doesn’t have that ceiling, so dosing is more straightforward.4PubMed. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin
A 2024 systematic review and meta-analysis comparing the two drugs head-to-head for neuropathic pain found that pregabalin produced greater reductions in pain scores over periods up to about three months, along with better quality-of-life measures and more days with no or only mild pain. People on pregabalin also used fewer opioids. Gabapentin, interestingly, caused more nausea and vomiting in the trials reviewed.5Frontiers in Pain Research. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety Not every study agrees on the magnitude of the difference, though. One smaller trial concluded gabapentin actually had fewer adverse effects overall than pregabalin and better patient adherence for long-term use.6PubMed Central. Efficacy of pregabalin, amitriptyline, and gabapentin for neuropathic pain The practical takeaway is that pregabalin is worth trying if gabapentin isn’t working well enough, but switching between the two won’t address concerns about the gabapentinoid class itself, since pregabalin carries similar risks of sedation, weight gain, and misuse potential. Pregabalin is actually classified as a Schedule V controlled substance in the U.S., a step gabapentin hasn’t reached federally.
Antidepressants for Nerve Pain
When the goal is to leave the gabapentinoid class entirely, antidepressants are one of the most studied alternatives for neuropathic pain. Two classes dominate the evidence: serotonin-norepinephrine reuptake inhibitors (SNRIs) like duloxetine and venlafaxine, and older tricyclic antidepressants like amitriptyline and nortriptyline.
Duloxetine is probably the most commonly substituted drug when someone stops gabapentin for diabetic neuropathy. A meta-analysis of head-to-head trials found no meaningful difference between duloxetine and gabapentin in pain relief, sleep improvement, or patients’ own ratings of how much better they felt.7PubMed. Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta-analysis of randomised controlled trials The side-effect profiles differ, though. Duloxetine tends to cause nausea and sometimes insomnia rather than sedation, which can be a welcome trade for people who found gabapentin too sedating.
Amitriptyline has decades of use behind it and remains a first-line option in many pain guidelines. In one pilot study of diabetic neuropathy, gabapentin actually outperformed amitriptyline on pain reduction and was far better tolerated: roughly a third of gabapentin patients reported side effects compared with over ninety percent on amitriptyline.8PubMed. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study That said, amitriptyline may have an edge in people with coexisting depression. A study in spinal cord injury patients found that amitriptyline was more effective than gabapentin specifically in participants who had higher depression scores at baseline, while for those with lower depression scores the drugs performed similarly.9PubMed. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury So if nerve pain and mood problems overlap, a tricyclic or SNRI can address both.
Other Anticonvulsants
Gabapentin is sometimes used for facial nerve pain like trigeminal neuralgia, but it’s not the strongest choice for that condition. Carbamazepine and oxcarbazepine are the established first-line drugs, working through a different mechanism that calms overactive sodium channels in the nerve.10PubMed Central. Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments When those two aren’t tolerated, lamotrigine and baclofen serve as second-line treatments.11PubMed Central. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. If you’ve been on gabapentin for trigeminal neuralgia and it’s not helping much, carbamazepine is the standard your provider will likely consider first.
Topical Treatments
Topical options are appealing when you want to avoid the whole-body side effects of oral medications. Two stand out for localized nerve pain. Lidocaine patches numb the skin over painful areas and are commonly used for the nerve pain that lingers after shingles. High-concentration capsaicin patches, which use the active compound in chili peppers, work differently: they temporarily desensitize pain-signaling nerve fibers in the skin. A trial in patients with diabetic nerve pain found that both lidocaine and capsaicin patches reduced pain meaningfully over six months, with lidocaine patches showing a slightly larger drop in average daily pain intensity.12PubMed Central. The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients
These patches won’t replace gabapentin for widespread pain, but for people whose nerve pain is concentrated in one area, like a patch of skin on the feet or the chest wall after shingles, they can be a reasonable substitute or add-on with almost no systemic side effects.
Alternatives for Restless Legs Syndrome
Gabapentin and its cousin gabapentin enacarbil (a prodrug version designed for more consistent absorption) have become first-line treatments for restless legs syndrome in recent years. The main competing option is dopamine agonists like pramipexole, ropinirole, and the rotigotine patch, which used to be the default first choice. They work well in the short term but carry a significant long-term risk called augmentation, where the restless legs symptoms actually get worse and start appearing earlier in the day.13PubMed. Restless Legs Syndrome and Other Movement Disorders of Sleep-Treatment Update Because augmentation is specifically tied to the dopamine pathway, gabapentinoids have a lower risk of it, which is a major reason they’ve been promoted to first-line status alongside dopamine agonists.
If you need to stop gabapentin for restless legs, the alternatives depend on your circumstances. Iron supplementation, including intravenous iron infusions, is recommended when iron stores are low. For severe cases that don’t respond to first-line drugs, low-dose opioids like tramadol or oxycodone are considered second-line therapy.14PubMed Central. Restless Legs Syndrome: Contemporary Diagnosis and Treatment That may sound surprising given the broader push away from opioids, but the doses used for restless legs are typically much lower than those used for pain, and guidelines recognize their role when other options have failed.
Alternatives When Gabapentin Is Used for Anxiety
Gabapentin is prescribed off-label for anxiety in some settings, but it’s not a guideline-recommended treatment for generalized anxiety disorder. The established first-line options are SSRIs like escitalopram and sertraline, SNRIs like venlafaxine, and pregabalin, which is actually approved for anxiety in Europe though not in the United States. Cognitive behavioral therapy is also first-line, with response rates in published studies ranging from about half to three-quarters of patients.15PubMed Central. The diagnosis and treatment of generalized anxiety disorder
Benzodiazepines work for short-term anxiety but carry a well-known addiction risk and generally shouldn’t replace gabapentin for long-term use. Buspirone is another non-addictive option, though its evidence base is smaller and less consistent than what exists for SSRIs. If you were prescribed gabapentin primarily for anxiety rather than pain, switching to an SSRI or starting therapy is likely a more evidence-based path.
Alternatives for Alcohol Use Disorder
Gabapentin has gained attention as an off-label treatment for alcohol use disorder, where it can help with both cravings and the insomnia and anxiety that often accompany early sobriety. A network meta-analysis found that gabapentin, along with several other drugs, improved total abstinence rates compared with placebo. The FDA-approved medications for alcohol use disorder, specifically naltrexone, acamprosate, and disulfiram, all also showed benefit, with disulfiram and baclofen producing some of the strongest effects on abstinence and reduced heavy drinking.16PubMed Central. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-Analysis
If reducing total drinking days is the primary goal rather than full abstinence, the evidence shifts somewhat. A separate analysis found that topiramate produced the largest reductions in total alcohol consumption compared with placebo, outperforming naltrexone and acamprosate on drinking-quantity measures, though topiramate’s side-effect profile is notably harsh.17PubMed. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate For most people, naltrexone or acamprosate will be the first alternatives a prescriber reaches for when stepping away from gabapentin, since they carry FDA approval and more robust safety data for this specific use.
Hot Flashes and Menopause Symptoms
Gabapentin is sometimes prescribed to reduce hot flashes in people who can’t or prefer not to take hormone therapy. It works modestly for this purpose, but a newer option has changed the landscape. Fezolinetant, sold as Veozah, is the first FDA-approved non-hormonal treatment designed specifically for menopausal hot flashes. It works by blocking a receptor in the brain’s temperature-regulation center, directly targeting the mechanism thought to cause vasomotor symptoms. Early assessments suggest it provides better symptom relief than older non-hormonal options, with a favorable tolerability profile.18PubMed Central. FDA approves Veozah (Fezolinetant) for menopausal symptoms: a new nonhormonal option If you’re taking gabapentin mainly for hot flashes, fezolinetant or another SNRI like venlafaxine (which also has evidence for hot flash reduction) may be worth discussing with your doctor.
Emerging Drug Options
One of the more promising recent developments in pain treatment is suzetrigine, a non-opioid pain drug approved by the FDA in early 2025 for moderate-to-severe acute pain. It works by selectively blocking a specific sodium channel found on pain-sensing nerves in the body, without crossing into the brain. That distinction matters because it means suzetrigine doesn’t cause the sedation, dependence, or respiratory depression associated with opioids or even some of the central-nervous-system effects of gabapentin.19PubMed Central. Suzetrigine, a Non-Opioid Small-Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science In a phase 3 trial across surgical and non-surgical acute pain conditions, the vast majority of participants rated suzetrigine’s effectiveness as good, very good, or excellent, and most side effects were mild.20PubMed Central. Suzetrigine, a Non-Opioid Na(V)1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain
Suzetrigine’s current approval is for acute pain, but trials are underway for chronic neuropathic conditions like diabetic peripheral neuropathy. If those pan out, it could become a direct alternative to gabapentin for one of its most common uses. It’s too early to call it a replacement, but it represents the kind of mechanistically targeted drug development that the chronic pain field has been waiting for.
Non-Drug Approaches
For chronic pain in particular, non-pharmacological strategies can either replace gabapentin or reduce the dose you need. Cognitive behavioral therapy has the strongest evidence base among psychological treatments, with multiple randomized controlled trials showing improvements in pain intensity and pain-related disability across a range of chronic pain conditions.21PubMed. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research It doesn’t “cure” pain, but it changes how the brain processes pain signals and reduces the fear-avoidance cycle that can make chronic pain worse over time.
Exercise is another intervention with real evidence behind it. A systematic review with expert consensus concluded that structured exercise programs reduce neuropathic pain intensity and can be considered an effective alternative or complementary therapy for most patients.22PubMed Central. Exercise for Neuropathic Pain: A Systematic Review and Expert Consensus For people with chemotherapy-induced peripheral neuropathy specifically, the evidence suggests exercise can reduce symptoms in people who already have neuropathy, though it hasn’t been shown to prevent it from developing in the first place.23PubMed Central. Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety
Spinal cord stimulation is a more invasive option, but for people with stubborn neuropathic pain, particularly after failed back surgery, it has strong evidence. A randomized controlled trial found that roughly half of patients receiving spinal cord stimulation achieved meaningful pain relief at six months, compared with fewer than one in ten patients managed with medications alone. The stimulation group also reported better quality of life, improved function, and higher treatment satisfaction.24PubMed. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome It’s not a first step, but for people who’ve tried multiple medications including gabapentin without success, it’s an underused option.25PubMed Central. Spinal cord stimulation for neuropathic pain: current perspectives
Supplements and Cannabis
Alpha-lipoic acid is the supplement with the most credible evidence for nerve pain, particularly diabetic neuropathy. Clinical trials have shown that a daily dose of 600 mg can improve neuropathic symptoms, likely through its antioxidant properties.26PubMed Central. Alpha-lipoic Acid and diabetic neuropathy In one study, half of patients rated their condition as “very much better” or “much better” after about six weeks of treatment, with improvements in pain scores, disability, and quality of life.27PubMed Central. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy It’s not as potent as prescription options, but it has a mild side-effect profile and is available over the counter, which makes it a reasonable add-on or a starting point for people with mild symptoms.
Cannabis-based medicines are a more complicated picture. A Cochrane review of the evidence for chronic neuropathic pain found that cannabis-based products slightly increased the proportion of people achieving meaningful pain relief compared with placebo, but the difference was small: about one in five people got at least 50 percent pain reduction with cannabis compared with about one in six with placebo. Meanwhile, twice as many people dropped out of trials due to side effects with cannabis compared with placebo.28PubMed Central. Cannabis‐based medicines for chronic neuropathic pain in adults The Cochrane reviewers concluded that the potential benefits might be outweighed by the harms. A separate meta-analysis found more promising results for products containing THC, which produced statistically significant reductions in pain intensity on a 100-point scale and increased the odds of achieving at least a 30 percent pain reduction. CBD alone, however, showed no significant benefit.29PubMed Central. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis
Some researchers have noted that the number-needed-to-treat for cannabis-based medicines in neuropathic pain trials is in a similar range to what you see with standard drugs like gabapentin and pregabalin.30PubMed. Medical Cannabis for Neuropathic Pain That doesn’t mean cannabis is equivalent, because the trial quality is generally lower and the long-term data are thin. But for people who’ve tried gabapentin and other first-line drugs without success, low-dose THC-containing products may be worth discussing where legal.
Tapering Off Gabapentin Safely
Whatever you’re switching to, the transition off gabapentin matters. Stopping abruptly can trigger withdrawal symptoms including anxiety, insomnia, sweating, nausea, and in rare cases seizures, even in people who weren’t taking it for epilepsy. Withdrawal has been documented after as little as three weeks of continuous use.31The Senior Care Pharmacist. Gabapentin: Change is in the Wind Experts have recommended that gabapentin tapers follow a slow schedule similar to what’s used for benzodiazepines, gradually reducing the dose over weeks to months rather than days.32PubMed. Gabapentin withdrawal syndrome in the presence of a taper
The pace of your taper will depend on your dose, how long you’ve been on gabapentin, and what condition it’s being used for. If you’re switching to pregabalin, some providers cross-taper by gradually introducing the new drug while slowly reducing gabapentin. If you’re moving to a completely different medication class, you may need the old drug tapered down first before the new one can be assessed on its own. Either way, this is not a do-it-yourself project. Work with your prescriber to set a schedule, and report any new symptoms during the taper so the timeline can be adjusted.
Kidney Disease and Special Populations
Gabapentin is cleared almost entirely by the kidneys, which makes dose adjustments critical for people with reduced kidney function. That same property creates problems when kidney disease is severe: the drug can accumulate and cause toxicity, including extreme sedation and confusion. For people with end-stage kidney disease, managing neuropathic pain requires careful attention to how each drug is metabolized, whether it produces toxic byproducts, and whether dialysis removes it.33PubMed Central. Pharmacotherapeutic Management of Neuropathic Pain in End-Stage Renal Disease
Duloxetine is processed through the liver rather than the kidneys, making it a common alternative in this population. Topical options like lidocaine patches avoid the issue entirely since they’re not absorbed in significant systemic amounts. For older adults more broadly, the sedation and fall risk from gabapentin and pregabalin are genuine concerns. Tricyclic antidepressants carry their own risks in this group, including cardiac effects and confusion, so the choice often comes down to the least-bad option given a person’s full medical picture. There’s no universal best alternative; there’s only the best alternative for a specific person.